- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novo's Long-Acting Insulin, Tresiba, Safe and Effective
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
Novo Nordisk's new long-acting insulin, Tresiba (insulin degludec), has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
Long-acting Tresiba is an important product for future growth at the company, which is the world's top insulin maker.
However, US regulators have refused to approve Tresiba due to potential heart risks, dealing a blow to the company. Tresiba was approved in the European Union last year.
Results of the first trial to look at the long-term safety of Tresiba in children aged 1 to 18 years over a 52-week period showed it improved blood sugar control without increasing the risk of hypoglycaemia.
Read the complete report: http://bit.ly/1uUeUWl
Source: Medscape
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
